Biotechnology

Aidea Pharma

Aidea Pharma released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 178.02 M, actual EPS CNY 0.02

Aidea Pharma to Release FY2026 Q1 Earnings on April 30 After-Market (BJT)

Aidea Pharma to Release FY2025 Earnings on March 31 During-Market (BJT), Forecast Revenue CNY 755.25 M

Aidea Pharma released FY2025 annual earnings on February 24 During-Market (BJT), actual revenue CNY 719.17 M (forecast CNY 755.25 M), actual EPS CNY -0.0464

Aidea Pharma released FY2025 Q4 earnings on February 24 During-Market (BJT), actual revenue CNY 166.77 M, actual EPS CNY -0.0192

Aidea Pharma released FY2025 Q3 earnings on October 30 After-Market (BJT), actual revenue CNY 189.92 M, actual EPS CNY -0.1498

Aidea Pharma released FY2025 9 Months Earnings on October 30 After-Market (BJT), actual revenue CNY 552.4 M, actual EPS CNY -0.1219

Aidea Pharma to Release FY2025 Q3 Earnings on October 31 After-Market BJT

Aidea Pharma released FY2025 Semi-Annual earnings on August 28 After-Market (BJT), actual revenue CNY 362.48 M, actual EPS CNY 0.02

Aidea Pharma released FY2025 Q2 earnings on August 28 After-Market (BJT), actual revenue CNY 164.62 M, actual EPS CNY -0.012

Aidea Pharma to Release FY2025 Semi-Annual Earnings on August 29, 2025 (BJT)

Eddia Pharmaceutical's stock price rises, Open Securities gives a buy rating

Opening Securities Gives Buy Rating to Aidi Pharmaceuticals

Aidephi's Anominet approved for drug registration in Zanzibar

Aidi Pharma Participates in HIV Drug Guideline Consultation

Eddingpharm Announces Stock Option Incentive Plan to Boost HIV New Drug Commercialization

Edi Pharmaceutical Receives Multiple 'Buy' Ratings from Securities Firms

Aide Philanthropy Discloses 2025 Stock Option Incentive Plan

Kaiyuan Securities Gives Buy Rating to Eddy Pharmaceutical

Edi Pharmaceutical Receives Multiple Buy Ratings from Brokers

002675

江苏鼎泰药物研究(集团)股份有限公司

688488

Jiangsu Aidea Pharmaceutical plans to pursue an IPO in Hong Kong to facilitate its expansion into the US and European markets. The company, currently listed on the Shanghai Stock Exchange, views Hong Kong as a strategic entry point due to its flexible fundraising environment. With expectations for the Aids treatment sector to exceed 10 billion yuan by 2027, Jiangsu Aidea aims to develop competitive products and has initiated discussions with Hong Kong's drug regulator. The company recently announced a financing plan of 1.2 billion yuan, primarily for US clinical projects.

SCMP

Dongcheng Biochem

China’s Jiangsu Aidea eyes Hong Kong IPO as gateway to US, European Aids markets

300016

688136

688710

300683

688131

The A-share innovative drug concept fluctuated and declined, with SDKX falling over 10%. INNOSTAR, HITECK, Aidea Pharma, Chemexpress, and Beilu Pharma had significant declines

Wallstreetcn

Beilu Pharma

SDKX

INNOSTAR

HITECK

Chemexpress

Aidea Pharma's wholly-owned subsidiary, Yangzhou Aidea Pharmaceutical Technology Co., Ltd., has received approval from the National Medical Products Administration to market the active pharmaceutical ingredient of Multilavir Sodium. This drug is used for the treatment of HIV infection and is suitable for adults and children over 12 years old. This approval will enhance the supply and quality of the active pharmaceutical ingredient, reduce production costs, and strengthen the company's competitiveness, but it is expected to have no significant impact on recent operations

Zhitong

Aidea Pharma: Sodium Dolutegravir API receives approval for listing application

Aidea Pharma announced on October 11th that the results of its self-developed anti-HIV drug Fubangde® SPRINT's Phase III clinical study have been published in BMC Medicine. This journal is a top medical journal with an impact factor of 9.4, and the influence of the published research results surpasses that of imported similar products

Aidea Pharma: The full text of the 96-week study on Fubangde® SPRINT was published in BMC Medicine

Aidea Pharma recently obtained the Drug Registration Certificate for Ainomi Tablets issued by the Zanzibar Food and Drug Authority. This drug is a compound anti-HIV-1 infection chemical drug developed independently by the company, based on the novel non-nucleoside reverse transcriptase inhibitor Ainovelin Tablets, which includes two nucleoside reverse transcriptase inhibitors: fumarate tenofovir disoproxil and lamivudine

Aidea Pharma: Ainomit Tablets Obtains Drug Registration Certificate in Zanzibar

Aidea Pharma participated in the "Guidelines for Clinical Drug Resistance Research and Data Submission for Anti-HIV Infection" released by the National Medical Products Administration, providing regulatory support for the research and development of anti-HIV drugs. The company was invited to attend a relevant expert consultation meeting in September 2024, demonstrating its leadership position in the domestic anti-HIV research and development field

New regulations for national HIV drug resistance research released, Aidea Pharma deeply involved

According to the Zhitong Finance APP, Aidea Pharma disclosed its 2025 stock option incentive plan (draft), proposing to grant a total of 11.375 million stock options, accounting for approximately 2.703% of the company's total equity at the time of the announcement of the incentive plan draft. Among them, 9.1 million options will be granted initially, with a total of 45 individuals as the initial grantees, and the exercise price is set at 13.01 yuan per option

Aidea Pharma plans to launch a stock option incentive plan for 11.375 million shares

688293

300485

688062

The biopharmaceutical sector continues to adjust, with *ST Four Rings hitting the daily limit down, Rongchang Bio falling over 18%, and Mabwell, SDKX, Science Sun Pharm, OPM, Aidea Pharma, and others following suit

Science Sun Pharm

Mabwell

REMEGEN

Aidea Pharma announced that due to significant changes in the project's objective environment and market prospects, the company and Nanjing Yaoshi Technology Co., Ltd. have mutually agreed to terminate the project cooperation development framework contract and the associated service contract ahead of schedule. This termination agreement will not have a significant impact on the company's operating performance for the year 2024 and will not affect the company's financial condition for 2025 and beyond. Aidea Pharma will continue to focus on the core development areas of anti-HIV drugs and human protein products, promoting steady growth in its main business

PHARMABLOCK

Aidea Pharma: Termination of the framework contract for the cooperative development of new drug projects with Pharmaron

688222

300723

688331

09995

This morning, innovative drugs suddenly became the market's main force, with the innovative drug index soaring nearly 6%. Stocks such as Chengda Pharmaceutical, Aidea Pharma, ApicHope, RemeGen, Jiankai Technology, and HitGen hit the daily limit or rose over 10%. Why did this long-silent sector suddenly explode? Analysts believe that, on one hand, this sector was not a hotspot before, nor was it crowded, and it is also suitable to become a defensive variety, thus becoming a direction for capital to attack; on the other hand, it is also related to some sudden positive news. First, the State-owned Assets Supervision and Administration Commission encourages state-owned enterprises to carry out mergers and acquisitions in the biopharmaceutical field. Second, there are strong expectations for the optimization of centralized procurement. On March 26, the National Healthcare Security Administration held a meeting to optimize the pharmaceutical centralized procurement work, and the market expects that the meeting may promote the optimization details of drug procurement. At the same time, the market is also discussing a document titled "Further Optimizing the Drug Procurement Policy (Draft for Comments)." Third, the National Medical Products Administration recently publicly solicited opinions on the "Measures to Optimize the Whole Life Cycle Supervision to Support the Innovative Development of High-end Medical Devices (Draft for Comments)."

Aidea Pharma(688488.SH)